Treatment failure in emergency department patients with cellulitis

Canadian Journal of Emergency Medicine

Volumn 7, Issue 4, 2005, Pages 228-234

  Murray, Heather ^a,c   Stiell, Ian ^b   Wells, George ^b  

^a QUEEN S UNIVERSITY   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c KINGSTON GENERAL HOSPITAL   (Canada)

Author keywords

Cellulitis; Skin and tissue infections; Treatment failure

Indexed keywords

ANTIBIOTIC AGENT;

ABSCESS DRAINAGE; ADOLESCENT; ADULT; AGED; ANTIBIOTIC THERAPY; CELLULITIS; CONTROLLED STUDY; DISEASE SEVERITY; EMERGENCY WARD; FEMALE; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; REVIEW; TREATMENT FAILURE;

EID: 27944458929     PISSN: 14818035     EISSN: 14818035     Source Type: Journal    
DOI: 10.1017/S1481803500014342     Document Type: Review

References (15)

1. Brown G, Chamberlain R, Goulding J, Clarke A. Ceftriaxone versus cefazolin with probenecid for severe skin and soft tissue infections. J Emerg Med 1996; 14(5):547-51.
2. Dong SL, Kelly KD, Oland RC, Holroyd BR, Rowe BH. ED management of cellulitis: a review of five urban centers. Am J Emerg Med 2001;19(7):535-40.
3. Grayson ML, McDonald M, Gibson K, Athan E, Munckhof WJ, Paull, et al. Once-daily intravenous cefazolin plus oral probenecid is equivalent to once-daily intravenous ceftriaxone plus oral placebo for the treatment of moderate-to-severe cellulitis in adults. Clin Infec Dis 2002;34(11):1440-8.
4. Deery HG. Outpatient parenteral anti-infective therapy for skin and soft-tissue infections. Infect Dis Clini N Am 1998;12(4):935-49, vii.
5. Leder K, Turnidge JD, Grayson ML. Home-based treatment of cellulitis with twice-daily cefazolin. Med Australia 1998;169(10):519-22.
6. Morris A. Cellulitis and erysipelas. Clin Evid 2002;(7): 1483-7.
7. Dilemmas when managing cellulitis. Drug Ther Bull 2003;41 (6):43-6.
8. Cox VC, Zed PJ. Once-daily cefazolin and probenecid for skin and soft tissue infections. Ann Pharmacother 2004;38(3):458-63.
9. Murray H. Cellulitis in the emergency department: developing and testing objective outcome measures [masters thesis]. University of Ottawa, 2002.
10. Eron LJ, Lipsky BA, Low DE, Nathwani D, Tice AD, Volturo GA, et al. Managing skin and soft tissue infections: expert panel recommendations on key decision points. J Antimicrob Chemother 2003;52(suppl 1):i3-17.
11. Calandra GB, Norden C, Nelson JD, Mader JT. Evaluation of new anti-infective drugs for the treatment of selected infections of the skin and skin structure. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis 1992; 15(suppl 1):S148-54.
12. Bibliography. Current world literature. Skin and soft tissue infections. Curr Opin Infect Dis 2004;17(2):149-57.
13. Montalto M, Dunt D. Home and hospital intravenous therapy for two acute infections: an early study. Aust N Z J Med 1997;27(1):19-23.
14. Hoogewerf SEC, Stiell IG, Vandemheen K. Single dose intravenous cefazolin and oral cephalexin compared to intravenous cefazolin for the treatment of cellulitis [abstract]. Can J Emerg Med 1999; 1 (3):184.
15. Zed PJ, Harder C, Harrison DW, Pursell RA. Efficacy of once daily cefazolin/probenecid for the outpatient management of skin and soft tissue infections [abstract]. Can J Emerg Med 2001;3(2):139-40.